Approval · Notice of Compliance 15160 · 2014
LUCENTIS: Notice of Compliance 15160
Issued January 28, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15160
- Date
- January 28, 2014
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- Addition to the indication: the treatment of visiual impairment due to chorooidal neovascularisation (cnv) secondary to pathologic myopia (pm)
- Therapeutic class
- Anti-neovascularisation agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUCENTIS | Not yet assigned | — |
Medicinal ingredients
- RANIBIZUMAB 10 MG per ML